Focus: Satellos Bioscience is a public biotech company focused on stimulating the body's innate tissue repair and regeneration mechanisms using biologic and small molecule drugs, primarily in rare diseases. The company is publicly traded (NASDAQ: MSLE) and headquartered in Toronto.
Profile data last refreshed 13h ago · AI intelligence enriched 3w ago
No open roles listed right now. Follow Satellos Bioscience to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Satellos Bioscience
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Satellos Bioscience's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update - TradingView
Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update TradingView
Satellos reports positive TRAILHEAD data for DMD drug - grafa.com
Satellos reports positive TRAILHEAD data for DMD drug grafa.com
Satellos’ ‘intriguing’ Duchenne data raise hopes ahead of key readout - Fierce Biotech
Satellos’ ‘intriguing’ Duchenne data raise hopes ahead of key readout Fierce Biotech
Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence - Yahoo Finance
Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence Yahoo Finance
FDA Fast Track boosts Satellos (NASDAQ: MSLE) SAT-3247 Duchenne program - Stock Titan
FDA Fast Track boosts Satellos (NASDAQ: MSLE) SAT-3247 Duchenne program Stock Titan
Satellos to Present Clinical Program Updates at ICNMD 2026 - GlobeNewswire
Satellos to Present Clinical Program Updates at ICNMD 2026 GlobeNewswire
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moRecent peer-reviewed publications with author affiliations at this company